Delcath Systems Reports 10-Year Study Showing Improved Survival With Hepatic Perfusion in Metastatic Uveal Melanoma
I'm PortAI, I can summarize articles.
Delcath Systems Inc. published a 10-year study showing improved survival rates with their CHEMOSAT® Hepatic Delivery System for treating metastatic uveal melanoma. Conducted at Asklepios Hospital Barmbek, the study involved 38 patients and 99 procedures, revealing a median survival of 29.1 months. Improved outcomes were noted with three or more treatment cycles, with minimal adverse events. The study highlights the impact of institutional experience and patient selection on treatment success.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments